Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended Decembe...(2008 our management and Board of Directo...)

Date:3/5/2009

2008, our management and Board of Directors determined to explore and pursue various restructuring and cost reduction initiatives in order to conserve our liquidity, as well as various financial and strategic transactions that could potentially reduce or eliminate our existing debt obligations and improve our working capital position.

On July 7, 2008, we announced that our Board of Directors had authorized a transaction to create a new subsidiary, Angiotech Pharmaceutical Interventions Inc. ("API"), and that we would contribute certain business assets and intellectual property to API, primarily consisting of business assets of Angiotech other than the intellectual property and royalty revenue related to TAXUS(R) coronary stent systems. In connection with this transaction, we were to receive $200 to $300 million of new financing from new investors to establish API, which financing was targeted to reduce substantial amounts of our existing debt obligations with equivalent amounts of convertible debt bearing interest in additional equity of the newly created subsidiary in kind, as opposed to cash. This transaction, if approved by our shareholders and completed, would have substantially reduced our annual cash pay interest obligations.

On September 22, 2008, we announced that we had postponed the planned shareholder vote regarding the proposed API transaction. As of that date, given the time required for more extended discussions to address concerns of certain of our shareholders and bondholders, and given various other factors impacting our business and cash position (including lower expected revenues derived from BSC), we did not believe we would be able to satisfy the transaction condition with respect to the minimum level of cash and cash equivalents required to be held at the time of the transaction's close.

On September 22, 2008, we also announced that we would pursue various initiatives to reduce operating costs and further focus our busin
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
2. Angiotech Pharmaceuticals announces time change of conference call and webcast
3. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
4. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
5. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. Angiotech wins before the UK House of Lords
8. Angiotech to Establish Separate Operating and Royalty Businesses
9. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
10. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study